<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<rss xmlns:ev="http://purl.org/rss/1.0/modules/event/" version="2.0">
    
    <channel>
      <title>Novavax Investor Relations</title>
      <link>https://ir.novavax.com/</link>
      <description/>
                  <item>
        <title>First Doses of R21/Matrix-M&#x2122; Malaria Vaccine Shipped to Africa </title>
        <link>https://novavax.investorroom.com/First-Doses-of-R21-Matrix-M-TM-Malaria-Vaccine-Shipped-to-Africa</link>
        <description>&lt;p&gt;Novavax, Inc. today celebrated the first shipment of R21/Matrix-M&#x2122; malaria vaccine by its partner, Serum Institute of India (SII).&lt;/p&gt;</description>
        <pubDate>05/20/2024</pubDate>
        <guid>https://novavax.investorroom.com/First-Doses-of-R21-Matrix-M-TM-Malaria-Vaccine-Shipped-to-Africa</guid>
      </item>
            <item>
        <title>R21/Matrix-M&#x2122; Malaria Vaccine Phase 3 Trial Results Published  
in The Lancet </title>
        <link>https://novavax.investorroom.com/R21-Matrix-M-TM-Malaria-Vaccine-Phase-3-Trial-Results-Published-in-The-Lancet</link>
        <description>&lt;p&gt;Today, peer-reviewed results from a Phase 3 efficacy trial of the R21/Matrix-M&#x2122; malaria vaccine were published in The Lancet. The trial was conducted across multiple sites in four African...&lt;/p&gt;</description>
        <pubDate>02/02/2024</pubDate>
        <guid>https://novavax.investorroom.com/R21-Matrix-M-TM-Malaria-Vaccine-Phase-3-Trial-Results-Published-in-The-Lancet</guid>
      </item>
            <item>
        <title>R21/Matrix-M&#x2122; Malaria Vaccine Granted Prequalification by World Health Organization</title>
        <link>https://novavax.investorroom.com/R21-Matrix-M-TM-Malaria-Vaccine-Granted-Prequalification-by-World-Health-Organization</link>
        <description>&lt;p&gt;The World Health Organization (WHO) announced today that it has prequalified the R21/Matrix-M&#x2122; malaria vaccine to prevent malaria disease in children caused by the P. falciparum parasite in...&lt;/p&gt;</description>
        <pubDate>12/21/2023</pubDate>
        <guid>https://novavax.investorroom.com/R21-Matrix-M-TM-Malaria-Vaccine-Granted-Prequalification-by-World-Health-Organization</guid>
      </item>
            <item>
        <title>R21/Matrix-M&#x2122; Malaria Vaccine with Novavax&#x2019;s Adjuvant Technology Receives WHO Recommendation </title>
        <link>https://novavax.investorroom.com/R21-Matrix-M-TM-Malaria-Vaccine-with-Novavaxs-Adjuvant-Technology-Receives-WHO-Recommendation</link>
        <description>&lt;p&gt;Strategic Advisory Group of Experts and Malaria Policy Advisory Group recommend use of R21/Matrix-M malaria vaccine in children to prevent malaria burden and disease in endemic areas...&lt;/p&gt;</description>
        <pubDate>10/02/2023</pubDate>
        <guid>https://novavax.investorroom.com/R21-Matrix-M-TM-Malaria-Vaccine-with-Novavaxs-Adjuvant-Technology-Receives-WHO-Recommendation</guid>
      </item>
                </channel>
  </rss>
